Krystal Biotech (NASDAQ: KRYS) announces quarterly earnings results

EPS FY2022 estimates for Krystal Biotech, Inc. (NASDAQ: KRYS) raised by William Blair


Krystal Biotech, Inc. (NASDAQ: KRYS – Get Rating) – William Blair analysts strengthened Krystal Biotech’s 2022 earnings estimates in a research report released Tuesday May 10 to clients and investors. William Blair analyst R. Prasad now expects the company to earn ($ 4.34) per share for the year, up from the previous forecast of ($ 4.50).

Krystal Biotech (NASDAQ: KRYS – Get Rating) last released its quarterly earnings data on Monday, May 9. The company posted ($ 0.99) EPS for the quarter, missing the ($ 0.89) consensus estimate of ($ 0.10).

KRYS has been the subject of several other research reports. Zacks Investment Research increased Krystal Biotech’s stock from a “hold” rating to a “buy” rating and set a $ 71.00 price target for the company in a research note on Thursday, May 5. On Tuesday, March 29, Guggenheim cut Krystal Biotech’s share price target from $ 114.00 to $ 101.00 in a research note. HC Wainwright cut Krystal Biotech’s share price target from $ 124.00 to $ 107.00 and set a “buy” rating for the company in a research note on Monday, February 28. Goldman Sachs Group lowered Krystal Biotech’s share price target from $ 125.00 to $ 93.00 and set a “buy” rating for the company in a report on Tuesday, March 1. Finally, Bank of America began hedging on Krystal Biotech shares in a report on Tuesday, Jan.18. They issued a “buy” valuation and a $ 110.00 price target for the company. Seven investment analysts rated the stock with a buy rating. According to MarketBeat, Krystal Biotech currently has a consensus rating of “Buy” and an average target price of $ 96.50.

Shares of NASDAQ: KRYS opened Friday at $ 50.93. The company has a 50-day moving average of $ 65.51 and a 200-day moving average of $ 62.51. Krystal Biotech has a 12-month low of $ 38.86 and a 12-month high of $ 102.99.

Numerous institutional investors and hedge funds have recently made changes to their positions in KRYS. Confluence Wealth Services Inc. acquired a new equity interest in Krystal Biotech in Q4 for approximately $ 25,000. Advisor Group Holdings Inc. purchased a new stock position in Krystal Biotech in Q3 for approximately $ 32,000. Widmann Financial Services Inc. acquired a new stake in Krystal Biotech during the fourth quarter valued at approximately $ 34,000. Great West Life Assurance Co. Can increased its stake in Krystal Biotech by 51.9% in the first quarter. Great West Life Assurance Co. Can now owns 1,013 shares in the company worth $ 72,000 after acquiring an additional 346 shares during the period. Finally, Lazard Asset Management LLC increased its stake in Krystal Biotech shares by 21.0% in the fourth quarter. Lazard Asset Management LLC now owns 1,272 shares in the company worth $ 88,000 after acquiring an additional 221 shares during the period. 76.57% of the stock is owned by institutional investors and hedge funds.

Kristal Biotech company profile (Get evaluation)

Krystal Biotech, Inc, a clinical stage biotechnology company, is engaged in the field of reasonable gene therapy for the treatment of severe rare diseases in the United States. Its flagship product is beremagene geperpavec (B-VEC), which is in a Phase III clinical trial for the treatment of dystrophic epidermolysis bullosa.

Recommended stories

History and Earnings Estimates for Krystal Biotech (NASDAQ: KRYS)



Get news and ratings for Krystal Biotech Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Krystal Biotech and related companies with MarketBeat.com’s FREE daily newsletter.

.

Leave a Comment

Your email address will not be published.